×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Articles

Kristie L. Kahl
In the second part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him about the past, present and future of the myeloma landscape.
Alyssa Castro
When I was diagnosed with Hodgkin's lymphoma, I envisioned myself in a galaxy far, far away. Just like any well-trained Jedi, I fought back when insurance denied my claim for doctor-recommended treatment.
Alexandra Guadagno
From cancer-sniffing dogs to music therapy for pain, here’s what is making headlines in the cancer space this week.
Kristie L. Kahl
In the first part of our Q&A with Chris Williams, of the Multiple Myeloma Research Foundation, we spoke with him on the current initiatives and resources available to patients.
Kristie L. Kahl
Routine use of prophylactic radiotherapy in patients with malignant pleural mesothelioma is unnecessary following a chest wall procedure, according to multicenter, open-label, phase 3, randomized controlled trial findings published in the Journal of Clinical Oncology.
Suzann B. Goldstein
What a force they were, those two daughters of ours: that little nine-year-old kid Valerie, gone from bone cancer and the more grown-up 37-year-old Stacy, cut off by breast cancer. When we talk of them, however, it is often with a slight grin.
Matthew Tontonoz
Results from a clinical trial in people with mesothelioma indicate that an experimental chimeric antigen receptor-T cell therapy is safe and may provide benefit to patients, especially in combination with other immunotherapies.
Katie Kosko
Patients with chronic lymphocytic leukemia should learn about the latest advancements, says one expert.

 
Brielle Benyon
The Food and Drug Administration approved Keytruda for the treatment of patients with metastatic small cell lung cancer.
Kristie L. Kahl
Maintenance therapy with defactinib failed to improve survival following front-line chemotherapy in patients with merlin-low malignant pleural mesothelioma, according to results from the phase 2 COMMAND trial.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other